More than 50 biotech leaders and investors are urging the FDA to disregard a methodologically flawed report on mifepristone.

Our health care system needs to do a better job of diagnosing and supporting people with cannabis-related diseases,” a ...

The people most at risk from suicide aren’t adolescents in angst or those experiencing a midlife lull, but men age 75 and ...

A new large study from Denmark finds no evidence that aluminum salts used in vaccines are tied to a higher risk of childhood ...

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

A pioneering reproductive technology reduced the risk of children inheriting disease-causing mutations in mitochondria, ...

Normally, the FDA is in the driver’s seat, determining proper oversight and regulations based on its scientific, medical, and ...

Robert F. Kennedy Jr. just named Mark Cruz, a Klamath member, his top tribal health adviser. In a Q&A, Cruz emphasized tribal ...

Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following ...

A federal judge has tossed out a lawsuit from Humana that attempted to reinstate higher quality ratings to its 2025 Medicare ...

The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...

Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.